Convalescent plasma therapy in the treatment of COVID-19: Some considerations: Correspondence.

Dear Editor, I would like to share ideas on “Convalescent plasma therapy in the treatment of COVID-19: practical considerations: Correspondence.” is very interesting [1]. Islam et al. noted that “While we await trial results, we recommend that CPT be considered for patients severely ill with COVID-19 upon hospitalization [1].” Convalescent plasma therapy is still not scientifically proven for its usefulness and safety. In fact, Islam et al. already mentioned for considerations on possible problem due to pathogen contamination in convalescent plasma [1]. At present, there is still no scientific proof that the presently use plasma preparation technique in all blood banks can successfully remove all pathogens. There are many other classic therapeutic options that might pose lower risk for management of COVID-19 such as the use of classic drug, hydroxychloroquine. Finally, whether the convalescent plasma can act against the novel coronavirus or not still requires further studies. There are some evidences on possible repeated COVID-19 infection in patients recovered from COVID-19 [2,3]. This can imply that there is a chance that there will be no protective immunity in plasma of patients recovered from a COVID-19 illness.

Sources of funding

None.

Ethical approval

Not applicable.

Unique identifying number (UIN)

Name of the registry: not applicable

Unique Identifying number or registration ID: not applicable

Hyperlink to your specific registration (must be publicly accessible and will be checked):

Author contribution

Wiwanitkit 100%.

Guarantor

Professor Viroj Wiwanitkit.

Provenance and peer review

Not Commissioned, internally reviewed.

Data statement

Not applicable.

Declaration of competing interest

None.